Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$4.57 +4.1%	$3.23	$1.03 ▼ $4.74	$979.52M	1.54	6.25 million shs	8.92 million shs
DNA Ginkgo Bioworks	$12.51 +6.4%	$11.55	$5.00 ▼ $16.85	$742.96M	1.5	1.53 million shs	1.73 million shs
SANA Sana Biotechnology	$3.58 -0.6%	$3.64	$1.26 ▼ $7.30	$851.35M	1.9	6.06 million shs	3.67 million shs
TNYA Tenaya Therapeutics	$1.13 -2.6%	$0.76	$0.36 ▼ $4.01	$184.16M	3.01	4.01 million shs	2.33 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	+17.78%	+22.19%	+121.84%	+243.61%
DNA Ginkgo Bioworks	0.00%	-4.95%	-16.14%	+78.94%	-17.71%
SANA Sana Biotechnology	0.00%	+7.51%	-30.21%	+79.90%	-32.45%
TNYA Tenaya Therapeutics	0.00%	-2.59%	+30.53%	+162.55%	-61.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.6027 of 5 stars	4.6	3.0	2.5	1.7	0.6
DNA Ginkgo Bioworks	1.068 of 5 stars	1.5	3.0	1.2	2.5	0.6
SANA Sana Biotechnology	2.9593 of 5 stars	3.5	3.0	1.4	3.3	0.6
TNYA Tenaya Therapeutics	2.8039 of 5 stars	3.5	1.0	2.1	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.17	Buy	$11.25	146.17% Upside
DNA Ginkgo Bioworks	3.00	Buy	$10.00	-20.05% Downside
SANA Sana Biotechnology	3.00	Buy	$8.00	123.46% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	453.10% Upside

Current Analyst Ratings Breakdown

Latest TNYA, DNA, ATAI, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	ATAI atai Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/30/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $15.00
7/29/2025	ATAI atai Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
7/28/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	3,159.79	N/A	N/A	$0.67 per share	6.82
DNA Ginkgo Bioworks	$227.04M	3.26	N/A	N/A	$10.35 per share	1.21
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.69	N/A	N/A	N/A	N/A	-85.43%	-64.38%	11/12/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$5.86	N/A	N/A	N/A	-136.56%	-43.25%	-22.29%	11/11/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$1.06	N/A	N/A	N/A	N/A	-91.96%	-43.07%	N/A
TNYA Tenaya Therapeutics	-$111.13M	-$0.96	N/A	N/A	N/A	N/A	-93.83%	-75.66%	11/5/2025 (Estimated)

Latest TNYA, DNA, ATAI, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ATAI atai Life Sciences	-$0.12	-$0.14	-$0.02	-$0.14	N/A	$0.72 million
8/11/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	-$0.16	+$0.04	-$0.39	N/A	N/A
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million
8/6/2025	Q2 2025	TNYA Tenaya Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.02	4.02	4.07
DNA Ginkgo Bioworks	N/A	5.41	5.41
SANA Sana Biotechnology	N/A	2.47	2.47
TNYA Tenaya Therapeutics	N/A	6.00	6.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
DNA Ginkgo Bioworks	78.63%
SANA Sana Biotechnology	88.23%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
DNA Ginkgo Bioworks	9.72%
SANA Sana Biotechnology	30.10%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	214.34 million	156.90 million	Optionable
DNA Ginkgo Bioworks	640	59.20 million	53.45 million	Optionable
SANA Sana Biotechnology	380	237.81 million	166.23 million	Optionable
TNYA Tenaya Therapeutics	110	162.98 million	83.69 million	Optionable

TNYA, DNA, ATAI, and SANA Headlines

Recent News About These Companies

Faraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

August 20, 2025 | marketbeat.com

Tenaya Therapeutics Reports Q2 2025 Financial Results

August 14, 2025 | tipranks.com

What is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?

August 11, 2025 | marketbeat.com

Q3 EPS Estimate for Tenaya Therapeutics Lifted by Analyst

August 11, 2025 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Hold

August 10, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at Chardan Capital

August 8, 2025 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 8, 2025 | globenewswire.com

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

August 7, 2025 | msn.com

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Tenaya (TNYA) Q2 Loss Narrows 59%

August 7, 2025 | fool.com

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025 | globenewswire.com

Equities Analysts Offer Predictions for TNYA Q1 Earnings

August 4, 2025 | marketbeat.com

Lifesci Capital Issues Negative Outlook for TNYA Earnings

August 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from Analysts

August 1, 2025 | marketbeat.com

Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies

July 30, 2025 | investing.com

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

July 30, 2025 | globenewswire.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, DNA, ATAI, and SANA Company Descriptions

atai Life Sciences NASDAQ:ATAI

$4.57 +0.18 (+4.10%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.55 -0.02 (-0.44%)

As of 08/22/2025 07:56 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Ginkgo Bioworks NYSE:DNA

$12.51 +0.75 (+6.36%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$12.70 +0.19 (+1.54%)

As of 08/22/2025 07:44 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$3.58 -0.02 (-0.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.62 +0.04 (+1.12%)

As of 08/22/2025 07:53 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Tenaya Therapeutics NASDAQ:TNYA

$1.13 -0.03 (-2.59%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.16 +0.03 (+2.65%)

As of 08/22/2025 07:58 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time